Cargando…
Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
BACKGROUND: Patients with COVID-19 receiving ritonavir-containing therapies are at risk of potential drug-drug interactions (pDDIs) because of ritonavir’s effects on cytochrome P450 3A4. OBJECTIVE: To assess the prevalence of pDDIs with ritonavir-containing COVID-19 therapy in adults with COVID-19 u...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394216/ https://www.ncbi.nlm.nih.gov/pubmed/36989455 http://dx.doi.org/10.18553/jmcp.2023.22366 |
_version_ | 1785083320368889856 |
---|---|
author | Igho-Osagie, Ebuwa Puenpatom, Amy Williams, Marissa Grifasi Song, Yan Yi, Denise Wang, Jessie Berman, Richard Gu, Miley He, Chujun |
author_facet | Igho-Osagie, Ebuwa Puenpatom, Amy Williams, Marissa Grifasi Song, Yan Yi, Denise Wang, Jessie Berman, Richard Gu, Miley He, Chujun |
author_sort | Igho-Osagie, Ebuwa |
collection | PubMed |
description | BACKGROUND: Patients with COVID-19 receiving ritonavir-containing therapies are at risk of potential drug-drug interactions (pDDIs) because of ritonavir’s effects on cytochrome P450 3A4. OBJECTIVE: To assess the prevalence of pDDIs with ritonavir-containing COVID-19 therapy in adults with COVID-19 using the Optum Clinformatics Data Mart database. METHODS: In this retrospective, observational cohort study, patients with COVID-19 aged 18 years or older prescribed cytochrome P450 3A4–mediated medications with supply days overlapping the date of COVID-19 diagnosis between January 1, 2020, and June 30, 2021, were classified as having pDDIs. pDDI was classified as contraindicated, major, moderate, or mild using established drug interaction resources. Prevalence of pDDIs with ritonavir-containing COVID-19 therapy was estimated for the entire cohort and in patient groups with high risk of severe COVID-19 progression or pDDIs. Actual COVID-19 treatments received by the patients, if any, were not considered. Outcomes were presented descriptively without adjusted comparisons. RESULTS: A total of 718,387 patients with COVID-19 were identified. The age-sex standardized national prevalence of pDDIs of any severity was estimated at 52.2%. Approximately 34.5% were at risk of contraindicated or major pDDIs. Compared with patients without pDDI, patients exposed to pDDIs were older and more likely to be female, reside in long-term care facilities, and have risk factors for progression to severe COVID-19. Higher prevalence of major/contraindicated pDDIs was observed in older patients (76.1%), female patients (65.0%), and patients with multiple morbidities (84.6%). CONCLUSIONS: Study findings demonstrate that more than one-third of patients with COVID-19 were at risk of significant pDDIs if treated with ritonavir-containing COVID-19 therapy and highlight the need to assess all patients with COVID-19 for pDDIs. Ritonavir-based therapies may not be appropriate for certain patient groups, and alternative therapies should be considered. |
format | Online Article Text |
id | pubmed-10394216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103942162023-08-03 Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy Igho-Osagie, Ebuwa Puenpatom, Amy Williams, Marissa Grifasi Song, Yan Yi, Denise Wang, Jessie Berman, Richard Gu, Miley He, Chujun J Manag Care Spec Pharm Research BACKGROUND: Patients with COVID-19 receiving ritonavir-containing therapies are at risk of potential drug-drug interactions (pDDIs) because of ritonavir’s effects on cytochrome P450 3A4. OBJECTIVE: To assess the prevalence of pDDIs with ritonavir-containing COVID-19 therapy in adults with COVID-19 using the Optum Clinformatics Data Mart database. METHODS: In this retrospective, observational cohort study, patients with COVID-19 aged 18 years or older prescribed cytochrome P450 3A4–mediated medications with supply days overlapping the date of COVID-19 diagnosis between January 1, 2020, and June 30, 2021, were classified as having pDDIs. pDDI was classified as contraindicated, major, moderate, or mild using established drug interaction resources. Prevalence of pDDIs with ritonavir-containing COVID-19 therapy was estimated for the entire cohort and in patient groups with high risk of severe COVID-19 progression or pDDIs. Actual COVID-19 treatments received by the patients, if any, were not considered. Outcomes were presented descriptively without adjusted comparisons. RESULTS: A total of 718,387 patients with COVID-19 were identified. The age-sex standardized national prevalence of pDDIs of any severity was estimated at 52.2%. Approximately 34.5% were at risk of contraindicated or major pDDIs. Compared with patients without pDDI, patients exposed to pDDIs were older and more likely to be female, reside in long-term care facilities, and have risk factors for progression to severe COVID-19. Higher prevalence of major/contraindicated pDDIs was observed in older patients (76.1%), female patients (65.0%), and patients with multiple morbidities (84.6%). CONCLUSIONS: Study findings demonstrate that more than one-third of patients with COVID-19 were at risk of significant pDDIs if treated with ritonavir-containing COVID-19 therapy and highlight the need to assess all patients with COVID-19 for pDDIs. Ritonavir-based therapies may not be appropriate for certain patient groups, and alternative therapies should be considered. Academy of Managed Care Pharmacy 2023-05 /pmc/articles/PMC10394216/ /pubmed/36989455 http://dx.doi.org/10.18553/jmcp.2023.22366 Text en Copyright © 2023, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Igho-Osagie, Ebuwa Puenpatom, Amy Williams, Marissa Grifasi Song, Yan Yi, Denise Wang, Jessie Berman, Richard Gu, Miley He, Chujun Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy |
title | Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy |
title_full | Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy |
title_fullStr | Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy |
title_full_unstemmed | Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy |
title_short | Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy |
title_sort | prevalence of potential drug-drug interactions with ritonavir-containing covid-19 therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394216/ https://www.ncbi.nlm.nih.gov/pubmed/36989455 http://dx.doi.org/10.18553/jmcp.2023.22366 |
work_keys_str_mv | AT ighoosagieebuwa prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy AT puenpatomamy prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy AT williamsmarissagrifasi prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy AT songyan prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy AT yidenise prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy AT wangjessie prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy AT bermanrichard prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy AT gumiley prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy AT hechujun prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19therapy |